Summary:

We may not talk about them the same way we talk about basketball or baseball players, but make no mistake, dancers are elite athletes. Their training is intense, and the competition is fierce. And with Breakdancing at the Olympics, dance content flooding TikTok, and dance competition shows all over TV, there's never been more interest in the art-form. So how do you take that global phenomenon, and harness it into a global business?

Dan Galpern is the CEO of DanceOne. In 2023, the company was formed out of the merger between Break The Floor Productions and Star Dance Alliance, and it has become the premier producer of educational and competitive dance events, as well as the largest family of dance brands in the world.

Dan joins us to discuss DanceOne's plans for future expansion and growth, and how their global community is raising up the next generation of world-class dancers.

Highlights:

• The origins of DanceOne (3:48)
• Path from investor to CEO (5:41)
• DanceOne infrastructure (6:46)
• Building the DanceOne experience (8:11)
• The global appeal of dance (9:20)
• DanceOne event offerings (10:30)
• Growth opportunities (11:43)
• The power of dance (15:29)
• The DanceOne community (17:52)
• Goals for the future (20:00)

Links:

Dan Galpern LinkedIn

DanceOne LinkedIn

DanceOne Website

ICR LinkedIn

ICR Twitter

ICR Website

Feedback:

If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.

The increasing popularity of Asian food presents many exciting business opportunities, but also some challenges. Many of these specialty restaurants are family-owned, and lack the corporate structure you'll find at larger chains. And a lot of them are located in rural places that make centralized distribution difficult. Servicing these types of businesses requires a personal touch, and a lot of relationship building to understand their individual needs. That makes the barrier to entry pretty high, and creates a pretty large moat around the companies already established in the sector.

That includes HF Foods Group, led by CEO Felix Lin. HF trades on NASDAQ under the symbol HFFG and they are a leading distributor of international and specialty foods service solutions to restaurants, wholesalers and other customers in the food supply chain in the United States. Before taking on the role of CEO, Felix served as President and Chief Operating Officer of HF Foods Group and has been a key part of developing, implementing, and executing on the company's comprehensive transformation plan.

Felix joins us to discuss how HF Foods Group made such strong inroads in the Asian food market, and how they plan to leverage their position in the marketplace, and smart capital allocation, to create opportunities for future growth.

Highlights:

• The history of HF Foods (3:17)
• The popularity of Asian foods (4:53)
• Customer loyalty (5:57)
• Product offerings (8:02)
• Navigating market disruptions (10:23)
• Distribution networks (12:32)
• M & A Strategy (14:00)
• Outlook for the international food space (17:34)
• Strategic plan for HF Foods (20:04)

Links:

Felix Lin LinkedIn

HF Foods Group LinkedIn

HF Foods Group Website

ICR LinkedIn

ICR Twitter

ICR Website

Feedback:

If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.

Innovating in the field of Med Tech presents a host of unique challenges. Formulating new treatments is a long and capital-intensive process. The regulatory regime for medical devices is extremely stringent. And even if you get approval, you still need to convince doctors that your treatment is safe and effective. But success in Med Tech R & D doesn't just mean profits for the company and it's shareholders, it means new treatments that can dramatically improve or even save the lives of patients.

Jim Clemmer became the CEO of AngioDynamics in April of 2016, the company trades on the NASDAQ under the symbol ANGO. Prior to joining the company, Jim served as President of the multi-billion dollar medical supply segment at Covidien PLC where he directed the strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operations, business development, and all other functions associated with the medical supplies business.

Jim joins us to discuss AngioDynamics' innovative products that are helping treat a range of conditions from pulmonary embolism to prostate cancer. He also explains how their continued commitment to innovation has set AngioDynamics up for future success.

Highlights:

• The AngioDynamics Mission (4:03)
• Managing the AngioDynamics Portfolio (5:04)
• What sets AngioDynamics apart in the field (6:20)
• Meeting real-world clinical needs (7:24)
• AngioDynamics products (8:53)
• AngioDynamics approach to R&D (12:45)
• The impact on patients (15:36)
• Navigating regulation in different markets (20:06)
• The role of AI (21:35)
• AngioDynamics' balance sheet (23:01)

Links:

AngioDynamics LinkedIn

AngioDynamics Website

ICR LinkedIn

ICR Twitter

ICR Website

Feedback:

If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.